Live Interview
And why does that matter?
This is how a Mato agent talks. Take the other seat: answer a few and feel it follow the thread.
Podcast charts
Published by Carl Haakon
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
On the charts
Every published chart this podcast appears in, in the snapshot behind this page. Each one links to the chart it came off.
From the feed
The latest episodes published to this podcast’s own RSS feed. Titles and descriptions are the publisher’s.
Episode 117 — 20 September 2026 Hospital system profit warnings signal access erosion; subcutaneous Alzheimer's delivery reshapes value narratives; FTC targets PBM insulin pricing; ICER expands early-phase evidence strategy. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 116 — 19 September 2026 Examining RWE gaps in supportive care for rare diseases, budget impact challenges for cell/gene therapies, and patient-centric shifts in European HTA methodologies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 115 — 18 September 2026 HCA's profit warning signals US access challenges; subQ Leqembi, FTC insulin settlement, and ICER advice expansion highlight evolving market access dynamics. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 114 — 17 September 2026 This week: CMS Medicare Advantage Star Ratings methodology shifts, FDA decentralized trials guidance, ICER's new gene therapy framework, and NICE's updated RWE guidance. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 113 — 16 September 2026 Examining evolving HTA methodologies, adaptive pathways, and US operational challenges in drug pricing and evidence generation. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 112 — 15 September 2026 Analyzing US healthcare access erosion signals, subcutaneous Alzheimer's therapy implications, insulin pricing competition impact, and early-phase HEOR strategy shifts. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 111 — 14 September 2026 CMS Part D redesign operational hurdles, ICER's Alzheimer's evidence framework evolution, EMA's rare disease pathway expansion, and FDA gene therapy designation updates reshape evidence strategies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 110 — 13 September 2026 HCA's profit warning signals US healthcare access challenges; new Leqembi formulation and FTC insulin settlement reshape value arguments; ICER expands early scientific advice. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 109 — 12 September 2026 Examining WHO's new health technology framework for resource-limited settings, Australia's TGA digital therapeutics updates, Canada's CADTH combination products pilot, and NICE's expanding global influence on HTA standards. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 108 — 11 September 2026 HCA's profit warning signals US hospital access erosion; subcutaneous Leqembi transforms Alzheimer's value assessments; FTC targets insulin pricing practices; ICER expands early-phase scientific advice. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 107 — 10 September 2026 CMS Part D gene therapy coverage shifts, FDA RWE guidance for post-marketing studies, NICE digital therapeutics framework updates, and EU Critical Medicines Act HTA timeline acceleration. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 106 — 09 September 2026 Examining emerging HTA frameworks in Asia-Pacific, RWE barriers in Latin America, gene therapy value strategies, and digital therapeutics integration hurdles. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 105 — 08 September 2026 HCA's profit warning signals access challenges; new Leqembi formulation and FTC settlement reshape pricing dynamics; ICER expands early-phase advice to align HEOR strategy. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 104 — 07 September 2026 HCA's profit warning signals access erosion, subcutaneous Leqembi challenges cost-effectiveness, FTC insulin settlement reshapes PBMs, and ICER expands early-phase advice. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 103 — 06 September 2026 This week: HCA's profit warning signals US access erosion, subcutaneous Leqembi approval shifts Alzheimer's HEOR, FTC insulin settlement reshapes competition, and ICER expands early-phase scientific advice. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 102 — 04 September 2026 Examining how US election outcomes may reshape drug pricing, AI's growing role in HTA evidence, oncology value-based pricing hurdles, and the evolving patient-centricity in HTA. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 101 — 03 September 2026 Examining HTA methodologies in humanitarian crises, incorporating social determinants, blockchain for RWE security, and post-Brexit access challenges in Northern Ireland. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 100 — 02 September 2026 Examining the evolving role of patient advocacy in evidence generation, ESG integration into pricing, value demonstration challenges for first-in-class drugs, and HTA development in low-resource settings. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 99 — 01 September 2026 Examining HCA's profit warning, subcutaneous Leqembi's HEOR challenges, FTC insulin settlement implications, and ICER's scientific advice expansion. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Episode 98 — 31 August 2026 Examining subcutaneous Leqembi’s access potential, HCA’s uninsured care surge, CVS insulin settlement dynamics, and ICER’s early-phase evidence shift. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Ranking source
Apple Podcasts rankings via the Mato Topic Intelligence Platform.
Observed September 20, 2026.
Apple and Apple Podcasts are trademarks of Apple Inc., registered in the U.S. and other countries.
Pairs with
Bring this source into Mato to read its transferable patterns, then turn them into an original show for your own audience.